Potassium Bicarbonate
Potassium
Sold as RESOLVE · Alka-Seltzer Gold · GAVISCON ADVANCE… · GAVISCON ADVANCE ANISEED… · GAVISCON ADVANCE -…
- Drug class
- Potassium
- Availability
- Over-the-counter
- Routes
- Oral
- Markets covered
- 2
- Products on record
- 11
- FDA reports (12 mo)
- 43
Overview
Plain-language summary, compiled from the cited regulatory records
Potassium bicarbonate is an active ingredient used for the relief of heartburn, acid indigestion, and sour stomach [1]. It belongs to the drug class of potassium supplements [1].
This ingredient is available under various brand names, including Alka-Seltzer Gold [1]. In the past 12 months, there have been 43 adverse event reports associated with potassium bicarbonate [2]. The most frequently reported reactions in these reports include diarrhea, fatigue, off-label use, dyspnea, and asthenia [2].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 10 | May 8, 2026 |
| US United States | FDA | 1 | December 4, 2025 |
GBUnited Kingdom· MHRA
10 products
Uses
Treatment of symptoms resulting from the reflux of acid, bile and pepsin into the oesophagus such as acid regurgitation, heartburn, indigestion (occurring due to the reflux of stomach contents), for instance, after gastric surgery, as a result of hiatus hernia, during pregnancy, accompanying reflux oesophagitis, including symptoms of laryngopharyngeal reflux such as hoarseness and other voice disorders, sore throats and cough.
It can also be used to treat the symptoms of gastro-oesophageal reflux during concomitant treatment with or following withdrawal of acid suppressing therapy.
How to take
USUnited States· FDA
1 product
Uses
Uses for the relief of ● heartburn ● acid indigestion ● sour stomach
How to take
Drug interactions
Known interactions involving Potassium Bicarbonate. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL000630613 · revised May 8, 2026
- [2]FDA DailyMed · 0824bedb-413b-2f… · revised December 4, 2025 [PDF]
- [3]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.